Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
OL Extension Study of LNP023 in C3G

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy

  • 0 views
  • 15 Jul, 2021
  • 9 locations
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

This is an open label safety and feasibility trial using Acthar in addition to the investigators center-specific standard therapy, which could include increase in maintenance immunosuppression, high dose IVIG (2 g/Kg), and/or Rituximab, in patients with CAMR.

  • 32 views
  • 26 Jan, 2021
  • 2 locations
Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

Idiopathic Nephrotic Syndrome (INS) is the first glomerulopathy in children and 60% of the patients develop Steroid-Dependant Nephrotic Syndrome (SDNS). Recently, rituximab (RTX), a humanized

  • 20 views
  • 24 Jan, 2021
  • 1 location
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

  • 0 views
  • 19 Jun, 2021
  • 38 locations
Safety and Efficacy Study of VIS649 for IgA Nephropathy

The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)

proteinuria
immunoglobulin a
nephropathy
immunoglobulins
  • 0 views
  • 28 Jan, 2021
  • 13 locations
Evaluation of a Renin Inhibitor Aliskiren Compared to Enalapril in C3 Glomerulopathy

glomerulopathy. Patients will be randomized to one or the other treatment for the first 6 months and then switch to the other treament for the following 2.5 years. Treatment will continue for altogether 3 years

mammogram
enzyme inhibitor
kidney biopsy
  • 0 views
  • 26 Jan, 2021
  • 4 locations
Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

Treatment with combination ACTHar gel and Tacrolimus therapy or ACTHar gel therapy alone in lowering urinary protein to creatinine (UP/Cr) ratios

h.p. acthar gel
insulin
tacrolimus
diabetes
type 2 diabetes mellitus
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

  • 0 views
  • 18 Apr, 2021
  • 2 locations
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Background Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and …

cyclosporine
nephropathy
angiotensin ii receptor antagonists
rituximab
immunosuppressive agents
  • 236 views
  • 28 Jul, 2021
  • 2 locations
Spleen Transplant in Solid Organ Transplantation

rejection . Most of these rejections can be successfully treated, but a high rate of transplant glomerulopathy and chronic antibody mediated rejection (AMR) leading to accelerated allograft failure is

  • 0 views
  • 10 Apr, 2021
  • 1 location